Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH. Das S, et al. Among authors: bryer d. Ann Rheum Dis. 2014 May;73(5):909-12. doi: 10.1136/annrheumdis-2013-204417. Epub 2014 Jan 2. Ann Rheum Dis. 2014. PMID: 24385201
Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients.
Coulthard LR, Geiler J, Mathews RJ, Church LD, Dickie LJ, Cooper DL, Wong C, Savic S, Bryer D, Buch MH, Emery P, Morgan AW, McDermott MF. Coulthard LR, et al. Among authors: bryer d. Clin Exp Immunol. 2012 Oct;170(1):36-46. doi: 10.1111/j.1365-2249.2012.04626.x. Clin Exp Immunol. 2012. PMID: 22943199 Free PMC article. Clinical Trial.
Shortening infusion times for infliximab administration.
Buch MH, Bryer D, Lindsay S, Rees-Evans B, Fairclough A, Emery P. Buch MH, et al. Among authors: bryer d. Rheumatology (Oxford). 2006 Apr;45(4):485-6. doi: 10.1093/rheumatology/kei247. Epub 2005 Dec 13. Rheumatology (Oxford). 2006. PMID: 16352636 No abstract available.
15 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page